FDA not taking action against weight loss compounders
The Trump administration has started quietly rehiring some of the U.S. Food and Drug Administration employees it fired last week, according to nine agency sources, shortly after letting them go in a ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...
President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...
In looking at the profound impact on satiety that GLP-1s have, Penn State College of Medicine Drs. Patrician Grigson and ...
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results